Regardless of disease stages, IL-17A and IL-23 exhibited higher levels in CRC patients than in CRA patients (IL-17A: P < 0.001 or P = 0.068; IL-23: P = 0.029 or P = 0.002), whereas IL-6 concentration was increased in the advanced CRCs (28.3 ± 3.3 pg/ml vs 21.7 ± 2.6 pg/ml, P = 0.154) but decreased in the advanced CRAs (27.7 ± 3.1 pg/ml vs 38.0 ± 2.4 pg/ml, P = 0.013) as compared with early stage of each disease. Here, IL6 is linked to colorectal carcinoma.